Super-Resolution Fluorescence Imaging Reveals That Serine Incorporator Protein 5 Inhibits Human Immunodeficiency Virus Fusion by Disrupting Envelope Glycoprotein Clusters.
DBSCAN
HIV-1 restriction
SERINC5
envelope glycoprotein clustering
super-resolution microscopy
viral fusion
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
22 09 2020
22 09 2020
Historique:
pubmed:
23
5
2020
medline:
15
5
2021
entrez:
23
5
2020
Statut:
ppublish
Résumé
Serine incorporator protein 5 (SERINC5) is the host antiretroviral factor that reduces HIV-1 infectivity by incorporating into virions and inhibiting the envelope glycoprotein (Env) mediated virus fusion with target cells. We and others have shown that SERINC5 incorporation into virions alters the Env structure and sensitizes the virus to broadly neutralizing antibodies targeting cryptic Env epitopes. We have also found that SERINC5 accelerates the loss of Env function over time compared to control viruses. However, the exact mechanism by which SERINC5 inhibits HIV-1 fusion is not understood. Here, we utilized 2D and 3D super-resolution microscopy to examine the effect of SERINC5 on the distribution of Env glycoproteins on single HIV-1 particles. We find that, in agreement with a previous report, Env glycoproteins form clusters on the surface of mature virions. Importantly, incorporation of SERINC5, but not SERINC2, which lacks antiviral activity, disrupted Env clusters without affecting the overall Env content. We also show that SERINC5 and SERINC2 also form clusters on single virions. Unexpectedly, Env and SERINC molecules exhibited poor codistribution on virions, as evidenced by much greater Env-SERINC pairwise distances compared to Env-Env distances. This observation is inconsistent with the previously reported interaction between Env and SERINC5 and suggests an indirect effect of SERINC5 on Env cluster formation. Collectively, our results reveal a multifaceted mechanism of SERINC5-mediated restriction of HIV-1 fusion that, aside from the effects on individual Env trimers, involves disruption of Env clusters, which likely serve as sites of viral fusion with target cells.
Identifiants
pubmed: 32441921
doi: 10.1021/acsnano.0c02699
pmc: PMC8274448
mid: NIHMS1714717
doi:
Substances chimiques
Glycoproteins
0
Membrane Proteins
0
SERINC2 protein, human
0
SERINC5 protein, human
0
Serine
452VLY9402
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10929-10943Subventions
Organisme : NIGMS NIH HHS
ID : R29 GM054787
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI150453
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM054787
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150453
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM103540
Pays : United States
Références
J Biol Chem. 2015 Mar 6;290(10):6558-73
pubmed: 25589785
EMBO J. 2003 Apr 1;22(7):1707-15
pubmed: 12660176
Nature. 2015 Oct 8;526(7572):212-7
pubmed: 26416734
Nat Struct Mol Biol. 2008 Jul;15(7):675-83
pubmed: 18596814
J Virol. 2016 Nov 14;90(23):10915-10927
pubmed: 27681140
Mol Immunol. 2017 Feb;82:19-33
pubmed: 28006656
Science. 2012 Oct 26;338(6106):524-8
pubmed: 23112332
J Virol. 2019 Jan 4;93(2):
pubmed: 30355687
PLoS Pathog. 2013 Feb;9(2):e1003198
pubmed: 23468635
J Virol. 2002 Nov;76(22):11584-95
pubmed: 12388719
Virology. 2018 Feb;515:52-65
pubmed: 29268082
Mol Membr Biol. 2003 Jul-Sep;20(3):243-54
pubmed: 12893532
Annu Rev Virol. 2018 Sep 29;5(1):323-340
pubmed: 30265629
Trends Microbiol. 2015 Dec;23(12):763-774
pubmed: 26541228
PLoS Pathog. 2007 May 4;3(5):e63
pubmed: 17480119
PLoS Pathog. 2008 Nov;4(11):e1000203
pubmed: 19008954
Biophys J. 2008 Mar 15;94(6):2320-32
pubmed: 18096627
Cell Rep. 2018 Jan 23;22(4):869-875
pubmed: 29386131
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13197-13202
pubmed: 27803322
Elife. 2013 Feb 19;2:e00333
pubmed: 23550179
Cell Rep. 2013 Nov 14;5(3):802-12
pubmed: 24209751
J Virol. 2005 Oct;79(19):12132-47
pubmed: 16160141
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25269-25277
pubmed: 31757854
Science. 2008 Feb 8;319(5864):810-3
pubmed: 18174397
AIDS. 2002 Nov 22;16(17):2253-61
pubmed: 12441796
J Virol. 2013 Jul;87(13):7516-25
pubmed: 23637402
J Virol. 2004 Jan;78(2):1026-31
pubmed: 14694135
Semin Cell Dev Biol. 2016 Dec;60:78-88
pubmed: 27401120
J Virol. 2018 May 14;92(11):
pubmed: 29514909
Methods Cell Biol. 2014;123:273-94
pubmed: 24974033
J Biol Chem. 2019 Apr 26;294(17):7013-7024
pubmed: 30862674
J Virol. 2017 Jan 31;91(4):
pubmed: 27928004
J Biol Chem. 2005 Oct 21;280(42):35776-83
pubmed: 16120614
J Biol Chem. 2017 Apr 7;292(14):6014-6026
pubmed: 28179429
Nature. 2015 Oct 8;526(7572):218-23
pubmed: 26416733
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2641-6
pubmed: 16481622
Cell Microbiol. 2013 Feb;15(2):292-304
pubmed: 23279151
Methods. 2018 May 1;140-141:172-177
pubmed: 29221925
Nat Struct Mol Biol. 2020 Jan;27(1):78-83
pubmed: 31907454
J Virol. 2017 Jun 26;91(14):
pubmed: 28446665
Nat Methods. 2011 Nov 06;8(12):1027-36
pubmed: 22056676
J Membr Biol. 2004 May 1;199(1):1-14
pubmed: 15366419
J Cell Biol. 2002 Nov 11;159(3):441-52
pubmed: 12417576
Biochemistry. 2008 Nov 11;47(45):11869-76
pubmed: 18937430
J Biol Chem. 2017 Aug 18;292(33):13702-13713
pubmed: 28659343
Nat Commun. 2019 Jan 8;10(1):78
pubmed: 30622256
J Virol. 2003 Aug;77(15):8237-48
pubmed: 12857892
Nat Methods. 2006 Oct;3(10):793-5
pubmed: 16896339
J Virol. 2008 Jun;82(11):5118-26
pubmed: 18353966
J Cell Biol. 2001 Nov 26;155(5):833-44
pubmed: 11724823
Biophys J. 2002 Nov;83(5):2634-51
pubmed: 12414697
J Virol. 2009 Feb;83(3):1523-31
pubmed: 19019953
J Biol Chem. 1998 Jun 19;273(25):15773-8
pubmed: 9624176
Virology. 2015 Dec;486:121-33
pubmed: 26432024
PLoS Pathog. 2015 Jan 08;11(1):e1004595
pubmed: 25569556
J Virol. 2019 Jun 28;93(14):
pubmed: 31043528